Difference between revisions of "Value frameworks"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200") Tags: mobile edit mobile web edit |
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") Tags: mobile edit mobile web edit |
||
| Line 5: | Line 5: | ||
=[https://www.asco.org ASCO Value Framework]= | =[https://www.asco.org ASCO Value Framework]= | ||
*'''2015:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427/ American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options] | *'''2015:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427/ American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options] | ||
| − | *'''2016:''' [https://doi.org/10.1200/jco.2016.68.2518 Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received] [https:// | + | *'''2016:''' [https://doi.org/10.1200/jco.2016.68.2518 Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received] [https://pubmed.ncbi.nlm.nih.gov/27247218 PubMed] |
=[https://www.esmo.org/Policy/ESCAT ESCAT]= | =[https://www.esmo.org/Policy/ESCAT ESCAT]= | ||
| Line 11: | Line 11: | ||
=[http://www.esmo.org/Policy/Magnitude-of-Clinical-Benefit-Scale ESMO Magnitude of Clinical Benefit Scale]= | =[http://www.esmo.org/Policy/Magnitude-of-Clinical-Benefit-Scale ESMO Magnitude of Clinical Benefit Scale]= | ||
| − | *'''2015 (Version 1.0):''' [https://annonc.oxfordjournals.org/content/26/8/1547.full.pdf+html A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)] [https:// | + | *'''2015 (Version 1.0):''' [https://annonc.oxfordjournals.org/content/26/8/1547.full.pdf+html A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)] [https://pubmed.ncbi.nlm.nih.gov/26026162 PubMed] |
*'''2017 (Version 1.1):''' [https://watermark.silverchair.com/mdx310.pdf ESMO-Magnitude of Clinical Benefit Scale version 1.1] | *'''2017 (Version 1.1):''' [https://watermark.silverchair.com/mdx310.pdf ESMO-Magnitude of Clinical Benefit Scale version 1.1] | ||
=[https://www.nccn.org/evidenceblocks/ NCCN Evidence Blocks]= | =[https://www.nccn.org/evidenceblocks/ NCCN Evidence Blocks]= | ||
| − | *'''2016:''' [http://www.jnccn.org/content/14/5S/616.long NCCN Evidence Blocks] [https:// | + | *'''2016:''' [http://www.jnccn.org/content/14/5S/616.long NCCN Evidence Blocks] [https://pubmed.ncbi.nlm.nih.gov/27226499 PubMed] |
=Comparisons= | =Comparisons= | ||
==ASCO Value Framework vs. ESMO-MCBS== | ==ASCO Value Framework vs. ESMO-MCBS== | ||
| − | *'''2017:''' [https://doi.org/10.1200/JCO.2016.71.6894 Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?] [https:// | + | *'''2017:''' [https://doi.org/10.1200/JCO.2016.71.6894 Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?] [https://pubmed.ncbi.nlm.nih.gov/28574778 PubMed] |
==ASCO Value Framework vs. NCCN Evidence Blocks== | ==ASCO Value Framework vs. NCCN Evidence Blocks== | ||
| − | *'''2017:''' [https://www.jmcp.org/doi/10.18553/jmcp.2017.23.6-a.s13 Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology] [https:// | + | *'''2017:''' [https://www.jmcp.org/doi/10.18553/jmcp.2017.23.6-a.s13 Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology] [https://pubmed.ncbi.nlm.nih.gov/28535103 PubMed] |
=Frequently asked questions= | =Frequently asked questions= | ||
Revision as of 19:07, 3 June 2021
Introduction
Several leading hematology/oncology societies and organizations have put forth value frameworks. Conceptually, these are approaches which are intended to combine measures of efficacy, toxicity, quality of life, and financial toxicity into a metric of value that can be used to influence treatment decisions. Our coverage of value frameworks will expand over time.
ASCO Value Framework
- 2015: American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- 2016: Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received PubMed
ESCAT
ESMO Magnitude of Clinical Benefit Scale
- 2015 (Version 1.0): A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) PubMed
- 2017 (Version 1.1): ESMO-Magnitude of Clinical Benefit Scale version 1.1
NCCN Evidence Blocks
- 2016: NCCN Evidence Blocks PubMed
Comparisons
ASCO Value Framework vs. ESMO-MCBS
- 2017: Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? PubMed
ASCO Value Framework vs. NCCN Evidence Blocks
- 2017: Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology PubMed
Frequently asked questions
| back to top |
Q: Do you plan to add value measures to HemOnc.org?
A: At some point in the future, we may add value measures to some regimens; however, given that these frameworks are recently introduced and undergoing frequent revision, we will continue to monitor their development, for now.